ALXO

insider transactions

ALX ONCOLOGY HOLDINGS INC — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

+3.2M

3.2M buy · 17.7K sell

Net value · 365d

$5.0M

$5.0M in · $34.3K out

Sentiment · 365d

Net buying

99% buying · 1% selling

Open-market trades · 365d

3.2M buy · 17.7K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Apr 16, 26

Jeff E. Knight

Chief Dev & Operating Officer

$0

800.0K sh

Own New
Grant·A
Apr 16, 26

Barbara Klencke

Chief Medical Officer

$0

100.0K sh

Own New
Sell·S
Mar 19, 26

Jason Lettmann KEY

CHIEF EXECUTIVE OFFICER

$26.7K

12.3K sh · $2.17

Own -4%
Sell·S
Mar 19, 26

Shelly Pinto

SVP, FINANCE AND CAO

$2.0K

903 sh · $2.17

Own -1%
Grant·A
Mar 3, 26

Barbara Klencke

Chief Medical Officer

$0

700.0K sh

Own New
Sell·S
Feb 18, 26

Shelly Pinto

SVP, FINANCE AND CAO

$1.3K

565 sh · $2.27

Own -1%
Other·F
Feb 17, 26

Jason Lettmann KEY

CHIEF EXECUTIVE OFFICER

$5.0K

2.2K sh · $2.27

Own -1%
Buy·P
Feb 2, 26

Corey S Goodman

Director, 10% Owner

$5.0M

3.2M sh · $1.57

Own +60%
Grant·A
Jan 26, 26

Harish Shantharam KEY

Chief Financial Officer

$0

303.0K sh

Own New
Grant·A
Jan 26, 26

Shelly Pinto

SVP, FINANCE AND CAO

$0

192.0K sh

Own New
Grant·A
Jan 26, 26

Jason Lettmann KEY

CHIEF EXECUTIVE OFFICER

$0

912.0K sh

Own New
Grant·A
Jan 20, 26

Corey S Goodman

Director, 10% Owner

$0

40.4K sh

Own New
Grant·A
Jan 20, 26

Scott J. Garland

Director

$0

40.4K sh

Own New
Grant·A
Jan 20, 26

Alan B. Sandler

Director

$0

10.1K sh

Own New
Grant·A
Jan 20, 26

Daniel J. Curran

Director

$0

16.8K sh

Own New
Grant·A
Jan 20, 26

Chris H Takimoto

Director

$0

40.4K sh

Own New
Grant·A
Jan 20, 26

Rekha Hemrajani

Director

$0

40.4K sh

Own New
Sell·S
Jan 6, 26

Shelly Pinto

SVP, FINANCE AND CAO

$4.4K

3.9K sh · $1.11

Own -4%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Apr 16, 2026	Jeff E. Knight	Chief Dev & Operating Officer	Grant A	800.0K	New	—	$0
Apr 16, 2026	Barbara Klencke	Chief Medical Officer	Grant A	100.0K	New	—	$0
Mar 19, 2026	Jason Lettmann KEY	CHIEF EXECUTIVE OFFICER	Sell S	12.3K	-4%	$2.17	$26.7K
Mar 19, 2026	Shelly Pinto	SVP, FINANCE AND CAO	Sell S	903	-1%	$2.17	$2.0K
Mar 3, 2026	Barbara Klencke	Chief Medical Officer	Grant A	700.0K	New	—	$0
Feb 18, 2026	Shelly Pinto	SVP, FINANCE AND CAO	Sell S	565	-1%	$2.27	$1.3K
Feb 17, 2026	Jason Lettmann KEY	CHIEF EXECUTIVE OFFICER	Other F	2.2K	-1%	$2.27	$5.0K
Feb 2, 2026	Corey S Goodman	Director, 10% Owner	Buy P	3.2M	+60%	$1.57	$5.0M
Jan 26, 2026	Harish Shantharam KEY	Chief Financial Officer	Grant A	303.0K	New	—	$0
Jan 26, 2026	Shelly Pinto	SVP, FINANCE AND CAO	Grant A	192.0K	New	—	$0
Jan 26, 2026	Jason Lettmann KEY	CHIEF EXECUTIVE OFFICER	Grant A	912.0K	New	—	$0
Jan 20, 2026	Corey S Goodman	Director, 10% Owner	Grant A	40.4K	New	—	$0
Jan 20, 2026	Scott J. Garland	Director	Grant A	40.4K	New	—	$0
Jan 20, 2026	Alan B. Sandler	Director	Grant A	10.1K	New	—	$0
Jan 20, 2026	Daniel J. Curran	Director	Grant A	16.8K	New	—	$0
Jan 20, 2026	Chris H Takimoto	Director	Grant A	40.4K	New	—	$0
Jan 20, 2026	Rekha Hemrajani	Director	Grant A	40.4K	New	—	$0
Jan 6, 2026	Shelly Pinto	SVP, FINANCE AND CAO	Sell S	3.9K	-4%	$1.11	$4.4K

About ALXO insider trading

This page tracks insider transactions for ALX ONCOLOGY HOLDINGS INC (ALXO) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.